Market: NMS |
Currency:
Address:
π NOMA Historical Chart
π Statistics
-
Analyst 1 Year Price Target:
-
-
Upside/Downside from Analyst Target:
-
-
Broker Call:
-
-
Dividend Minimum 3 Year Yield:
-
-
EPS Growth Range (1Y):
-
-
Net Income Growth Range (1Y):
-
-
Revenue Growth Range (1Y):
-
-
Upcoming Earnings Date:
-
π° Dividend History
No dividend history available.
π
Earnings & EPS History for NOMA
No earnings history available for this symbol.
π° Related News & Research
-
Aura Biosciences Reports 2025 Financial Results and Advances Phase 3 CoMpass Trial for Choroidal Melanoma
March 30, 2026
Aura Biosciences Reports Q4 & FY2025 Results: Clinical Progr...
-
Nomadar Secures Strategic Investments to Accelerate Global Sports Technology Platform Expansion
March 30, 2026
Nomadar Corp: Strategic Capital Investment and Accelerated G...
-
Williams-Sonoma, Inc. 2026 Annual Report: Growth Strategies, Cybersecurity, and Risk Management in the Home Retail Industry
March 26, 2026
Williams-Sonoma, Inc. 2026 Annual Report β Detailed Investor...
-
SinoMab Announces Favorable Phase 1 Bridging Study Results for SM17 Subcutaneous Formulation in China, Plans Phase 2 Clinical Trial for Atopic Dermatitis
March 26, 2026
SinoMab BioScience Announces Positive Topline Results for SM...
-
Nomadar Corp. Assigns Naming Rights for JP Financial Arena BahΓa de CΓ‘diz in Landmark Sponsorship Agreement
March 16, 2026
NOMADAR CORP. β Assignment Agreement of Naming Rights & Shar...
-
SinoMab BioScience Limited Announces Board Meeting to Approve 2025 Final Results on March 23, 2026 1
March 11, 2026
SinoMab BioScience Limited Announces Date of Board Meeting t...
-
Nanjing Leads Biolabs Enrolls First Patient in Phase II Trial of Opamtistomig (LBL-024) for First-Line Esophageal Squamous Cell Carcinoma 1
March 6, 2026
Nanjing Leads Biolabs Co., Ltd. Announces First Patient Enro...
-
Nomadar Corp. 8-K SEC Filing Details and Securities Purchase Agreement (March 2026)
March 6, 2026
Nomadar Corp. Announces Private Placement and Entry into Mat...
-
Delcath Systemsβ CHOPIN Phase 2 Trial Shows Improved Survival with Combined Hepatic Perfusion and Immunotherapy in Metastatic Uveal Melanoma (Published in The Lancet Oncology)
March 4, 2026
Delcath Systems Announces Landmark CHOPIN Trial Results in T...
-
Sinomax Group Limited Announces Board Meeting to Approve 2025 Annual Results and Consider Final Dividend
March 2, 2026
Sinomax Group Limited Announces Date of Board Meeting for 20...
π View more Reports